 |
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
 |
     |
|
 |
|
 |
 |
 |
|
Angelica Therapeutics is an exciting young company focused on developing potent cancer therapeutics. We are building a pipeline of fusion toxins based on our proprietary new version of one of the most potent toxins known, Diphtheria toxin (DT). Fusion toxins are single chain recombinant molecules comprised of a ligand and a protein toxin. The ligand provides specificity and promotes internalization of the toxin into a target cell. Through a contractual arrangement with Antitope Ltd we are producing a non-immunogenic DT to incorporate into our fusion toxins. Specifically, we have altered all the T cell epitopes in the DT molecule to extend the half life of all fusion proteins that include this improved DT moiety.
Our lead product candidate is a fusion of DT and interleukin-2 (IL-2). This will be a low risk follow on product to an existing drug, Ontak®. Ontak® is approved for the treatment of cutaneous T cell lymphoma (CTCL). We anticipate that our product will offer a substantial improvement in bioavailability over the current product. A non-immunogenic DT-IL2 will allow for chronic administration and should therefore have greater and more sustained effects.
|
|
|
|
 |
|